骨质疏松症的联合治疗与序贯治疗

被引：20

作者：

夏维波

机构：

[1] 中国医学科学院北京协和医学院北京协和医院内分泌科卫生部内分泌重点实验室

来源：

中华骨质疏松和骨矿盐疾病杂志 | 2011年 / 4卷 / 02期

关键词：

骨质疏松症; 联合治疗; 序贯治疗;

D O I：

暂无

中图分类号：

R580 [];

学科分类号：

摘要：

联合和序贯治疗骨质疏松症是为了追求更大疗效的一种选择,本文检索分析近45年来发表的此类临床研究结果。目前尚无证据表明两种抗骨吸收联合治疗有降低骨折发生率的叠加作用(如双膦酸盐加ERT或雷洛昔芬,雌激素加降钙素),仅观察到联合治疗可以降低骨转换和增加骨密度的结果。联合甲状腺激素(PTH)同抗骨吸收药物,随着药物的不同对骨密度的效果各异。在停止使用促进骨形成剂PTH后序贯使用双膦酸盐、雷洛昔芬或锶盐,可以防止因停用PTH后的骨丢失,可能成为未来治疗严重的绝经后骨质疏松症的重要选择。

引用

页码：73 / 81

页数：9

共 11 条

[1]

Effects of continuous combined hormone replacement therapy and clodronate on bone mineral density in osteoporotic postmenopausal women: A 5-year follow-up [J].

Tuppurainen, Marjo ;

Harma, Kirsi ;

Komulainen, Marja ;

Kiviniemi, Vesa ;

Kroger, Heikki ;

Honkanen, Risto ;

Alhava, Esko ;

Jurvelin, Jukka ;

Saarikoski, Seppo .

MATURITAS, 2010, 66 (04) :423-430

[2]

Effects of Teriparatide, Alendronate, or Both in Women with Postmenopausal Osteoporosis [J].

Finkelstein, Joel S. ;

Wyland, Jason J. ;

Lee, Hang ;

Neer, Robert M. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (04) :1838-1845

[3]

Effect of Strontium Ranelate on Lumbar Spine Bone Mineral Density in Women with Established Osteoporosis Previously Treated with Teriparatide [J].

Anastasilakis, A. D. ;

Polyzos, S. A. ;

Avramidis, A. ;

Papatheodorou, A. ;

TerpoS, E. .

HORMONE AND METABOLIC RESEARCH, 2009, 41 (07) :559-562

[4]

Parathyroid Hormone(1–84) Treatment of Postmenopausal Women with Low Bone Mass Receiving Hormone Replacement Therapy.[J].I. Fogelman;J. N. Fordham;W. D. Fraser;T. D. Spector;C. Christiansen;S. A. Morris;J. Fox.Calcified Tissue International.2008, 2

[5]

Addition of monofluorophosphate to estrogen therapy in postmenopausal osteoporosis: A randomized controlled trial [J].

Reid, Ian R. ;

Cundy, Tim ;

Grey, Andrew B. ;

Horne, Anne ;

Clearwater, Judith ;

Ames, Ruth ;

Orr-Walker, Brandon J. ;

Wu, Fiona ;

Evans, Margaret C. ;

Gamble, Gregory D. ;

King, Alan .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (07) :2446-2452

[6]

Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial) [J].

Ringe, J. D. ;

Farahmand, P. ;

Schacht, E. ;

Rozehnal, A. .

RHEUMATOLOGY INTERNATIONAL, 2007, 27 (05) :425-434

[7]

Randomized trial comparing low-dose hormone replacement therapy and HRT plus 1α-OH-vitamin D<Subscript>3</Subscript> (alfacalcidol) for treatment of postmenopausal bone loss.[J].Hideki Mizunuma;Masataka Shiraki;Masafumi Shintani;Itsuo Gorai;Kazuya Makita;Shunichi Itoga;Yoshiko Mochizuki;Hiromichi Mogi;Yasuhisa Iwaoki;Shouichirou Kosha;Toshiyuki Yasui;Osamu Ishihara;Takumi Kurabayashi;Yoshio Kasuga;Kunihiko Hayashi.Journal of Bone and Mineral Metabolism.2006, 1

[8]

Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass:: a randomized, controlled trial [J].

Reginster, JY ;

Felsenberg, D ;

Pavo, I ;

Stepan, J ;

Payer, J ;

Resch, H ;

Glüer, CC ;

Mühlenbacher, D ;

Quail, D ;

Schmitt, H ;

Nickelsen, T .

OSTEOPOROSIS INTERNATIONAL, 2003, 14 (09) :741-749

[9]

Addition of Alendronate to Ongoing Hormone Replacement Therapy in the Treatment of Osteoporosis: A Randomized; Controlled Clinical Trial*.[J].Robert Lindsay;Felicia Cosman;Rogerio A Lobo;Brian W Walsh;Steven T Harris;Jane E Reagan;Charles L Liss;Mary E Melton;Christine A Byrnes.The Journal of Clinical Endocrinology & Metabolism.1999, 9

[10]

COHERENCE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH GROWTH-HORMONE AND CALCITONIN [J].

ALOIA, JF ;

VASWANI, A ;

MEUNIER, PJ ;

EDOUARD, CM ;

ARLOT, ME ;

YEH, JK ;

COHN, SH .

CALCIFIED TISSUE INTERNATIONAL, 1987, 40 (05) :253-259

← 1 2 →